: Internal identifiers from clinical registries like the Norwegian Arthroplasty Register (NAR).
: The Phase 3 MOVE trial demonstrated that palovarotene reduced the volume of new heterotopic ossification (HO) by approximately 62% compared to untreated patients. JB_JB.BOYS.rar
If this refers to a specific digital archive (a .rar file), it is not a publicly documented dataset. It may represent: : Internal identifiers from clinical registries like the